True enough. It comes down to balancing what might be made on this stock against what might be made on other investments while waiting. Given that the phase 1 trials are all about safety and nothing about efficacy and gains based on results are unlikely to produce substantial persistent rerates. My estimate, and that's all it is, is that the price is unlikely to rise and hold above $0.50 any time in the next twelve months.
NSB Price at posting:
34.0¢ Sentiment: Hold Disclosure: Held
